G40.C
Lafora progressive myoclonus epilepsy
Clinical Classification Guidelines
Inclusion Terms
- Lafora body disease
Code Also
- , if applicable, associated conditions such as dementia (F02.8-)
Medical Intelligence & Overview
Lafora progressive myoclonus epilepsy, also known as Lafora body disease, is a rare and severe neurological disorder that causes recurrent seizures, muscle jerks, and progressive neurological decline. It typically begins in adolescence or early adulthood and progresses over time, significantly impacting quality of life. The condition is characterized by the accumulation of abnormal glycogen-like substances called Lafora bodies in various tissues, especially in the brain, leading to widespread neurological dysfunction.
Causes & Symptoms
Clinical Causes: Genetic mutations in the EPM2A gene or NHLRC1 gene, both of which are involved in glycogen metabolism Inheritance pattern is autosomal recessive, meaning a person must inherit two copies of the defective gene—one from each parent—for the disease to develop These genetic mutations lead to the formation of abnormal Lafora bodies within neurons, disrupting normal brain function
Key Symptoms: Myoclonus: sudden, involuntary muscle jerks or spasms, often affecting the limbs or face Seizures: including generalized tonic-clonic seizures, absences, and myoclonic seizures Progressive neurological decline: worsening coordination, difficulty walking, and cognitive impairment Difficulty with balance and gait as the disease advances Visual disturbances and decline in mental functions over time Potential for behavioral changes and psychiatric symptoms in some cases
Diagnostic & Treatment
Diagnosis Path: Diagnosis primarily involves clinical assessment of symptoms, family history, and neurological examinations. Confirmation is achieved through genetic testing to identify mutations in the EPM2A or NHLRC1 genes. Additionally, brain imaging techniques such as MRI can reveal atrophy or other structural changes. Electroencephalography (EEG) may demonstrate characteristic abnormal brain activity, especially during seizures. A skin or brain biopsy showing Lafora bodies can provide further confirmation, although genetic testing remains the gold standard.
Treatment Protocols: Currently, there is no cure for Lafora disease. Treatment focuses on managing symptoms and improving quality of life. Antiepileptic medications, such as valproate, levetiracetam, or clonazepam, are used to control seizures and myoclonus. Supportive therapies include physical, occupational, and speech therapy to assist with motor functions and communication. Because of the progressive nature of the disorder, multidisciplinary care involving neurologists, genetic counselors, and other specialists is essential. Ongoing research aims to find targeted therapies that can slow or halt disease progression.
Clinical Advice & FAQs
Billing Guidance
Is G40.C a billable ICD-10 code?
Yes, G40.C is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G40.C?
Clinical documentation must specify the nature of Lafora progressive myoclonus epilepsy and any associated comorbidities for accurate reporting.
Cite this Clinical Reference